(NewMediaWire) - March 04, 2019 - DALLAS - The American Heart Association and its division, the American Stroke Association, join the chorus of organizations and individuals sending heartfelt condolences to the family, friends and fans of actor Luke Perry. Media reports indicate that Perry, age 52, died today following what has been described as a “massive stroke” on Thursday. A stroke can happen to anyone at any age, however, the risk does go up with age. "Athough stroke often affects older individuals, it is not only a disease of the elderly. Luke Perry's tragic death highlights the fact that stroke can affect middle aged and young adults, even children. In fact, there is evidence that stroke rates among young people are increasing in the United States and this requires additional research," said Mitchell S.V. Elkind M.D., M.S., chair of the American Stroke Association Advisory Committee and a professor of Neurology and Epidemiology at Columbia University and attending neurologist at Columbia University Medical Center of the NewYork-Presbyterian Hospital. "While we don't know the cause of Perry's stroke, it's important for people to know the risk factors for stroke." Those include smoking, high blood pressure, diabetes, high cholesterol, obesity and other cardiovascular diseases such as atrial fibrillation, or AFib (a heart rhythm disorder) and family history. Stroke is the No. 2 cause of death worldwide and a leading cause of disability. Many people may not know that often strokes are treatable. The faster you are treated, the more likely you are to recover. The acronym F.A.S.T. is an easy way to remember how to recognize a stroke and what to do. Spot a stroke FAST. Face drooping. Arm weakness. Speech Difficulty. Time to call 9-1-1. Stroke can be caused either by a clot obstructing the flow of blood to the brain (called an ischemic stroke) or by a blood vessel rupturing and preventing blood flow to the brain (called a hemorrhagic stroke). Treatment options depend on the type of stroke. It has not been reported what type of stroke Perry experienced. To learn more about lowering your risk for stroke, visit www.strokeassociation.org. ### About the American Heart Association The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1. About the American Stroke Association Stroke is the No. 2 cause of death worldwide and a leading cause of disability. The American Stroke Association is a relentless force for a world with fewer strokes. We team with millions of volunteers to create world of longer, healthier lives by funding innovative research, fighting for stronger public health policies, and providing lifesaving tools and information to prevent, treat and beat stroke. The Dallas-based association was created in 1998 as a division of the American Heart Association. To learn more or to get involved, call 1-888-4STROKE or visit strokeassociation.org. Follow us on Facebook and Twitter. For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Management Aims to Setup a World-Class Green Tech Campus in New YorkThe Company aims to harness their proprietary technology through multiple biomass processing facilities to cater to the rising demand of ethanol, carbon fibre, and other products.MILTON, GA - (NewMediaWire) - March 4, 2019 - Attis Industries (ATIS) took its first big step in the field of renewable energy when the Company acquired the ethanol production facility of Sunoco LP in Fulton, New York. Through its renewable energy vertical known as Attis Innovations, the company is working towards disrupting the fossil fuel industry by revolutionizing the processing of biomass in order to sustainably produce ethanol and other bi-products. Attis Innovations not only seeks to achieve cost advantage and profitability with their novel technologies, but to also preserve the environment via their ongoing efforts to create shared value for stakeholders. The recently acquired Fulton plant currently has the capability to produce 85 million gallons of ethanol and other products like CO2, dried distilled grains, and corn oil. The output of the Fulton plant represents Attis potentially adding over $160 million in revenues based on the following projections:· 85 Million gallons of Ethanol @ ~ $1.39 = $118,150,000· 350 Million pounds (175,000 TONS) of CO2 @ $10 per ton = $1,750,000· 480 Million pounds of Dried Distilled Grains @ $0.08 per pound = $38,400,000· 1.5M Gallons of Corn Oil @ $1.73 per gallon = $2,600,000Attis’ acquisition journey has just commenced and the management team, led by CEO Jeffery Cosman, intends to purchase additional land of approximately 300 to 400 acres near the current 134-acre Fulton facility with the goal of building a world-class green tech campus. The additional land will be used for setting up a biodiesel plant that can use the corn extract produced as a bi-product from the ethanol facility to create biodiesel. The Company also plans to establish a bio-refinery within the same campus, which will effectively result in the creation of more than 300 jobs. As of today, the management team is working towards streamlining processes and eliminating bottlenecks within the ethanol facility, which is expected to increase the output of the plant by about 20% and enable the plant to produce around 100 million gallons of ethanol each year; an increase of 15 million gallons of ethanol, which represents a projection of an additional $20 million plus of revenue. Over a long-term horizon, the management also plans to add a solar project and a wind energy project near the same site.The operations facilities of Attis Innovations are expected to be geographically diversified as the management intends to set up or acquire additional ethanol plants in other US states such as Georgia, Florida, and South Carolina over the next two years. The Company is also looking at international expansion through strategic partnerships with companies in various countries such as Malaysia, Indonesia, Philippines, Brazil, UK, Argentina, and Canada.The research and development activity of Attis is in full swing, as there are a number of potential patents in the development pipeline. The Company anticipates a very strong opportunity in the carbon fibre market, which Attis can enter through the use of its proprietary technology to extract better cellulosic value as well as lignin from biomass. The company is developing the capability to produce high-quality carbon fibre with a good tensile strength through the lignin extracted through biomass processing. Being significantly lighter and stronger than steel, carbon fibre has immense application in the automobile, aeronautical, and aerospace industries. CEO Jeff Cosman notes, “Having a significant cost advantage with respect to the production of carbon fibre through biomass is not the only benefit of Attis’ technology. We are able to produce high-quality carbon fibre without releasing more carbon into the atmosphere unlike fossil fuels. Our ways are not only more cost-effective but also more beneficial to the ...
Las Vegas, NV - (NewMediaWire) - March 04, 2019 - Golden Matrix Group Inc. (OTCPK: GMGI) a technology-driven company that designs and develops social gaming platforms, systems and gaming content, today announced that for the second fiscal quarter ended January 31, 2019, the company recorded net income of $421,791 on revenues of $713,542. This compares with net income of $84,484 on revenues of $30,000 in like year-ago quarter.Second quarter 2019 revenues and net income represent 2,278 and 399 percent increases, respectively, on revenues and net income recorded in the second quarter of 2018.For the first six months ended January 31, 2019, Golden Matrix reported net income of $753,790 on revenues of $1,352,237, compared with a net loss of $373,559 on revenues of $60,000 in the like year-ago period.Revenues recorded in the first half of fiscal 2019 were derived primarily from licensing fees received from gaming operators located in the Asia Pacific (APAC) region and integrated with the company’s state-of-the-art GM-X platform. Currently there are 192 active operators and more than 1.5 million registered users across all gaming operator/GM-X platforms.“These excellent Q2 results further demonstrate GMGI’s continued growth and success in servicing the robust Asia-Pacific gaming markets, the largest in the world,” said CEO Brian Goodman. “As previously stated, we expect the company to continue to increase market share throughout 2019 and maintain strong positive cash flow with rising profitability.”Mr. Goodman noted that cash and cash equivalents as of January 31, 2018 increased 150% to $1,118,499 from $446,581 at fiscal year-end (July 31) 2018. Total assets increased to $1,828,435, up 123% from $819,874 at fiscal year-end 2018.For additional information on Golden Matrix’s Q1 2019 performance, please refer to the Company's 10-Q filing at https://www.otcmarkets.com/stock/GMGI/disclosure or www.sec.gov.About Golden MatrixGolden Matrix Group, based in Las Vegas NV, is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers, located primarily in the Asia Pacific region. The gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company's platform can be accessed through both desktop and mobile applications.Our sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with current US law.Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.Connect with us:Twitter - https://twitter.com/GMGI_GroupInstagram - https://www.instagram.com/goldenmatrixgroup/Golden Matrix GroupTracy Wanginfo@goldenmatrix.comTel: (702) 318-7548www.goldenmatrix.com GOLDEN MATRIX GROUP, INC Consolidated Balance ...
eHealth publishes results from survey of more than 800 short-term health insurance enrollees SANTA CLARA, Calif. , March 4, 2019 /PRNewswire/ -- A new survey of consumers who purchased short-term health ...
Vancouver, British Columbia - (NewMediaWire) - March 04, 2019 - Phyto Pharma Inc. (www.phytopharma.ca), a Vancouver, British Columbia based phytopharmaceutical and intellectual property holding company with operations in three United States jurisdictions including Colorado, California, and Puerto Rico, today announced that the Company has sold approximately $500,000 US worth of Hemp raw material to California and Colorado based labs within the month of March before the end of first quarter 2019. The Hemp raw material will be used for isolate based products for nutraceutical grade use.The Vancouver based Company contracts for the production of specific strains of high CBD biomass through strategic licensed green house and farm tolling operations based in Colorado, incorporates proprietary extraction methods for CBD oil and finally, engages in the formulation, development, and commercialization of cannabinoid-based products.Phyto Pharma brands including Phytocine™ and Rehab Rx™ are manufactured from proprietary strains of whole plant hemp extracts, containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids, and other valuable hemp compounds.The passage of the US 2018 Farm Bill signed by President Trump at the end of 2018 will now allow Phyto Pharma to expand its hemp biomass cultivation from raw material extraction to consumer products containing specific genetic strains and IP owned by the Company. Phyto Pharma seeks to utilize our genetic specific strains which contain high strains of cannabis derived CBD and aid in the manufacturing process specifically for pharma or nutraceutical based products for the targeted treatment of specific conditions and disease.“We are extremely pleased with the recent increase in revenue and demand for our Hemp based raw material from our Colorado farming operations. The recent orders of close to $500,000 US for the month of March alone demonstrates strong growth and demand for our proprietary extracted Hemp material to both the pharma and nutraceutical sectors. We look forward to completing the review process and recently announced acquisition by Vinergy Resources Ltd. giving us access to the public markets in both the US and Canada,” stated Phillip Johnston, Esq., CEO of Phyto Pharma Inc.Legalization and acceptance of CBD for its health and wellness benefits is accelerating at a rapid pace globally. CBD is presently most commonly being used for anxiety, insomnia, pain and nausea, but is being investigated as a treatment for other conditions. Earlier this year, the U.S. FDA approved the CBD drug, Epidiolex, for the treatment of childhood epilepsy. The World Health Organization has also recommended descheduling CBD as a controlled substance among its 194-member states. The Brightfield Group of Chicago forecasts the market for CBD from hemp could reach US$22 billion by 2022.Phyto Pharma is not making specific therapeutic claims. The use of the term pharmaceutical, pharmaceutical grade, pharmaceutical dosage forms, etc. are indicative of the process by which new formulation products will be created with the intent of accurately identifying specific strains, the active ingredients and measured amount to be used in each dosage form using best practices associated with traditional pharmacy formulations. Phyto Pharma is seeking to take existing anecdotal evidence and through its own formulation process further identify which cannabis varieties and strains are best suited to aid in a specific disease. The goal is to provide a reliable clinical effect through the use of well-crafted and well-researched oil analytics and dosage forms including oral and transdermal delivery of IP mapped cannabis extracts and nutraceutical and pharma brands.About Phyto Pharma Inc.Phyto Pharma Inc. (www.Phytopharma.ca) is a phytopharmaceutical and intellectual property holding company that has been created to develop innovative cannabis products, using accepted pharmaceutical formulation techniques, to reliably produce identifiable and replicable dosage forms for the targeted treatment of ...
Supported by Contract from U.S. Agency for International Development (USAID)Atlanta, GA - (NewMediaWire) - March 04, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has expanded its collaboration activities with Leidos, Inc. to develop malaria vaccine candidates. The work will be supported under a contract to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP). Leidos has been tasked by USAID to advance promising vaccine candidates against P. falciparum malaria and selected the GeoVax MVA-VLP platform as part of this development effort.GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression and budding from the infected cells. In this way, vaccination strategy mimics a natural viral infection which induces two pools of proteins – virus-infected cells and released multimeric or VLP proteins.Farshad Guirakhoo, PhD, GeoVax’s Chief Scientific Officer, commented, “Currently there is a shortage of malaria vaccine candidates that can offer the high efficacy rates (e.g. >75%) set by the World Health Organization (WHO) as a requirement for the second-generation malaria vaccines. Although protein-derived vaccines can deliver multiple antigens in immunogenic VLP conformation, they hardly produce a balanced functional cellular immune response needed to confer a high protection. In contrast, vectored-derived live vaccines are capable of producing the appropriate balanced immune responses, but they suffer from limitations in delivering the required number of transgenes needed to protect against all stages of malaria parasite. GeoVax’s MVA-VLP platform can overcome both limitations of antigen conformation and transgene capacity by delivering multiple transgenes (e.g. from parasite’s liver stage, blood stage and mosquito stage) in the form of VLPs delivered in vivo. This new collaboration with Leidos complements our ongoing malaria vaccine development project with Burnet Institute in Australia and offers multiple opportunities for success.”David Dodd, GeoVax’s President and CEO, said, “We are delighted to broaden our relationship with Leidos to include malaria vaccines. This remains a significant unmet healthcare need and we believe that this collaboration has the potential to result in a significant improvement in this critical area. Our hope is to successfully proceed through product development and identify promising vaccine candidates that can be taken into clinical development as quickly as possible, demonstrating an effective, safe vaccine for malaria prevention. We are confident that our technology, combined with Leidos' has an excellent chance for success.”About GeoVaxGeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, ...
Company Books Additional 41 Franchise Commitments for $2,238,000 in Deferred Revenues and Secures 47 New Locations for its Franchisees and 19 Degrees Fund SAN DIEGO, CA - (NewMediaWire) - March 04, 2019 - Generation NEXT Franchise Brands, Inc. (OTCQB: VEND) announced its monthly report to stakeholders for the month of February today. The report is part of a continued effort announced last month to keep all Company stakeholders better informed of key operating metrics and in a transparent environment. Key highlights and metrics for February: Booked 41 new Reis & Irvy’s franchise commitments worth $2.2 million in deferred revenue (averaging $319,745 per franchise sale and $54,585 per robot sold). Monthly revenue of $228,000 resulting from the installation of 6 robots at an average of $38,000 revenue recognized per robot.Secured 47 new locations for Reis & Irvy’s kiosks. In January, Generation Next announced the launch of 19 Degrees Corporate Service LLC (“19 Degrees”) to provide Reis & Irvy’s robots to locations outside of existing franchise territories and provide a structure to investors to own robotic frozen yogurt vending kiosks operated by the Company in return for passive income. In February, the 19 Degrees subsidiary:Added 22 units of 19 Degrees which resulted in the Company collecting $291,000 of investment to be used for the purchase and installation of robots.Secured seven new locations for 19 Degrees.As of February 28th, the Company has: sold a total of 57 units of 19 Degrees, resulting in $1.0 million invested; secured 78 locations which are scheduled for installation between April and June 2019.“We’ve received positive reports from our franchisees and locations about the performance of Reis & Irvy’s during February,” said Nick Yates, CEO of Generation Next Franchise Brands. “Our engineering solutions and manufacturing improvements are having the impact we expected. Our month-over-month results will continue to improve as we finish upgrading existing kiosks and gradually increase the pace of our new robot installations.” Generation Next and its franchisees discovered defects in the first batch of kiosks assembled and installed during the second half of calendar year 2018, resulting in a production halt that persisted until late February, when the Company resumed kiosk production and began upgrading existing kiosks with redesigned hardware and software. February installation numbers were negatively impacted as a result of this production halt.Yates recently received this note from a Houston franchisee regarding the upgrades: “Nick, Improvements have been observed in recent testing of the 0.71 software, along with Stoelting firmware updates, on one of our machines with a history of HVB Errors. We have been monitoring consistencies and temperature cycles as compressors cool the cylinders and then the hoppers, all working as would be expected. The units do not seem to be over-working, as they were in the past. This appears to be a good collaboration between Stoelting and ReThink. Thanks! Regards, Michael and Michelle Bingham” From March through June 2019, the Company estimates it will install an additional 100 to 150 robots bringing the total robots installed for the fiscal year ended June 30, 2019 to between 290 and 340 with annual revenue recognized of $11.0 to $12.9 million. From July to December 2019, Generation Next expects to install 600 to 800 additional robots and recognize between $22.8 and $30.4 million in revenue. For more information, visit the Reis & Irvy’s website at www.reisandirvys.com or call Toll-Free (888) 902-7558. Generation NEXT Website: www.gennextbrands.com About Generation NEXT Franchise Brands, Inc. Generation NEXT Franchise Brands, Inc., based in San Diego, California, is a publicly traded company on the OTC Markets trading under the symbol OTCBB: VEND. Generation NEXT Franchise Brands, Inc. is parent company to Reis and Irvy’s Inc and 19 Degrees Corporate Service LLC About Reis & Irvy’s, Inc. Reis & Irvy’s, Inc. is a subsidiary franchise concept of Generation NEXT Franchise ...
Newport Beach, CA - (NewMediaWire) - March 04, 2019 - ADVANTIS CORPORATION (OTC PINK: ADVT) announced today that it is preparing for the audit necessary for their OTCBB up-listing. Advantis is currently trading in the less regulated, more thinly traded OTC Pink Sheets.Advantis has been preparing for their fully-reporting status since 2017. The previous CEO set the initial target for the end of last year. The current CEO, Darren Cherry, says he delayed the up-listing so the company could be in a more solid financial position. “Our revenue continues to increase, we are establishing brand recognition, and have several opportunities to expand upon,” Cherry related. “This year our revenue will be well over a million, and several product launches are ahead. We’re ready.” Cherry says that up-listing will put Advantis in a more liquid exchange, and the more stringent reporting requirement will boost confidence that investors have in them. “This is the paramount step for our company. The step that will make so much more possible. There will be many more eyes on us with the opportunity to benefit from our continued growth,” Cherry asserted.The timing of the up-listing coincides with several product launches, Cherry explained, “Between now and the time we are a fully-reporting company we have the sublingual launch, the Pet Division… we’re looking at about four or five months until the process is completed and the form is filed. It will be real nice to have some additional revenue streams activated just as we become established on the OTC Big Board.” Cherry concluded his comments by saying that the legal and accounting arrangements are underway.Advantis wishes to thank Investors Hangout for mentioning the company in their podcast. Links to Advantis websites can be found at advantiscorp.com, rosin6.com, elixicure.com, and amstercan.com About Advantis CorporationAdvantis Corporation (ADVT) focuses on the development of innovative products that supply the medical, research, and pharmaceutical industries. The company additionally establishes partnerships with businesses that develop and sell proprietary pain management, and consumer products and services. Forward Looking Statements: This news release contains forward-looking statements made by ADVANTIS CORPORATION. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward- looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward looking statements. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 because it is not registered under either Act. For further information, contact: Media Relations Contact Name: Woo Kim, Director Organization: Advantis Corporation Phone: 949-354-3585 Address: 1048 Irvine Ave. #900 Newport Beach, CA 92660 E-mail: info@advantiscorp.com
Ft. Lauderdale, FL - (NewMediaWire) - March 04, 2019 - Cardiff Lexington Corporation (OTC:CDIX) announced today the retirement of eight convertible notes entered into by the Company between September 2016 and November 2018.“We have made significant inroads to reduce debt. Today’s announcement demonstrates our commitment to improve the Company’s balance sheet and strengthen our financial foundation,” stated Alex Cunningham, Cardiff Lexington’s CEO. “The elimination of several variable rate, floating price, convertible notes has strengthened our balance sheet and simplified our capital structure. We will continue working to restructure the Company for future growth.” As a result, the Company’s eight (8) convertible notes which had been currently convertible at variable prices reflecting a predetermined discount to market prices, have been retired and the Company has eliminated this indebtedness. About Cardiff Lexington Corporation: Cardiff Lexington is a public holding company, much like a cooperative, leveraging proven management in private companies that become subsidiaries. Our focus is not industry or geographic-specific, but rather proven management, market, and margin. Cardiff Lexington targets acquisitions of mature, high growth, niche companies. Cardiff Lexington's strategy identifies and empowers select income-producing middle market private businesses and commercial real estate properties. Cardiff Lexington provides these companies both 1) the enhanced ability to raise money for operations or expansion, and 2) an equity exit and liquidity strategy for the owner, heirs, and/or Investors. For investors, Cardiff Lexington provides a diversified lower risk to protect and safely enhance their investment by continually adding assets and holdings. Cardiff Lexington is led by strong and talented team of executives and advisors providing expert acquisition, market guidance and added value for subsidiaries and investors. FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.Investor Relations 844-628-2100 ext. 705 investorrelations@cardifflexington.com
Toronto, Ontario - (NewMediaWire) - March 04, 2019 - NexTech AR Solutions (the “Company” or “NexTech”) (CSE: NTAR) (OTC: NEXCF)(FSE:N29) today announced that its CEO, Evan Gappelberg, is scheduled to appear live on Cheddar TV this afternoon at 1:10pm ET.Gappelberg will be showcasing NexTech’s AR for eCommerce technology, including the new ‘Try-It-On’ functionality and updated user experience, as well as sharing his predictions for the future of augmented reality and the eCommerce industry.Viewers can tune into the Cheddar news segment by live streaming on Cheddar’s website or downloading the Cheddar app in the Apple Store or Google Play.Cheddar is the leading post-cable, live-streaming video news network focused on covering the most innovative executives, founders, products, and technologies transforming our lives and economy.About NexTech AR Solutions Corp.NexTech is bringing augmented reality (AR) to the Cannabis industry and to the masses by creating an AR ecosystem featuring eCommerce solutions for websites, AR learning and education tools, and AR live streaming for events. With just a few lines of embed code, the Company’s patent-pending technology can integrate into existing eCommerce platforms, providing retailers with a highly scalable platform that increases customer engagement and sales. To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.nextechar.com.On behalf of the Board of NexTech AR Solutions Corp.“Evan Gappelberg”CEO and DirectorThe CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.For further information, please contact: Evan Gappelberg Chief Executive Officer info@nextechar.com Media contact: Erin Hadden FischTank Marketing and PR ehadden@fischtankpr.com
